title: Efficacy of oral colon-specific delivery capsule of low-molecular-weight heparin on ulcerative colitis.
abstract: Low-molecular-weight heparin has the potential for the treatment of ulcerative colitis, and targeted drug delivery to the colon is important for topical treatment of this disease, so low-molecular-weight heparin oral colon-specific delivery capsule was prepared, and the in vitro and in vivo drug release behavior was investigated. The macroscopical and histological scoring systems, wet colon mass index and myeloperoxidase activity were assessed to evaluate the efficacy of the capsule after administered orally to experimental colitis mice. Serum levels, including tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6) and a link factor of blood coagulation and inflammation factor Xa (FXa) were assayed by enzyme-linked immunosorbent assay. The expression of Musashi-1 (as an intestinal stem cell marker) in the colons was assessed by immunohistochemical analysis. The in vitro and in vivo drug release studies clearly indicated that the specific coated capsules were capable of protecting low-molecular-weight heparin from releasing in stomach and small intestine, while specifically delivering at colon. The oral colon-specific delivery capsule of low-molecular-weight heparin could attenuate macroscopic and histological features of colitis. The results showed that low-molecular-weight heparin oral colon-specific delivery capsule significantly decreased the serum levels of TNF-α, IL-6 as well as FXa, while increased the expression of Musashi-1 in colon compared with acetic acid-induced ulcerative colitis model group. The results showed that low-molecular-weight heparin oral colon-specific delivery capsule had the potential for treatment of inflammatory bowel disease.
authors.affiliation: Institute of Biochemical and Biotechnological Drugs, Shandong University, Jinan 250012, China.
authors.forename: Jun-Yong
authors.initials: JY
authors.lastname: Luo
authors.forename: Yan
authors.initials: Y
authors.lastname: Zhong
authors.forename: Ji-Chao
authors.initials: JC
authors.lastname: Cao
authors.forename: Hui-Fei
authors.initials: HF
authors.lastname: Cui
mesh_terms: D000284:Administration, Oral; D000818:Animals; D000925:Anticoagulants / Q000008:administration & dosage / Q000494:pharmacology*; D003093:Colitis, Ulcerative / Q000188:drug therapy* / Q000473:pathology; D003106:Colon / Q000378:metabolism; D017985:Dalteparin / Q000008:administration & dosage / Q000494:pharmacology*; D004195:Disease Models, Animal; D016503:Drug Delivery Systems; D004797:Enzyme-Linked Immunosorbent Assay; D015951:Factor Xa / Q000378:metabolism; D005260:Female; D015850:Interleukin-6 / Q000097:blood; D008297:Male; D051379:Mice; D009419:Nerve Tissue Proteins / Q000378:metabolism; D016601:RNA-Binding Proteins / Q000378:metabolism; D014409:Tumor Necrosis Factor-alpha / Q000097:blood
chemical_list: D000925:Anticoagulants; D015850:Interleukin-6; C104786:Msi1h protein, mouse; D009419:Nerve Tissue Proteins; D016601:RNA-Binding Proteins; D014409:Tumor Necrosis Factor-alpha; D015951:Factor Xa; D017985:Dalteparin